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Abstract: The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing  
unfolded or misfolded proteins in the cell from aggregating. In Alzheimer’s disease, extracellular accumulation of the 
amyloid  peptide (A) and intracellular aggregation of the microtubule associated protein tau may result from mecha-
nisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins 
like A and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. 
This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimer’s 
disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating 
Hsp27 for treating Alzheimer’s disease. 
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INTRODUCTION 
  The chaperone system of heat shock proteins (Hsps) is an 
ancient and evolutionarily conserved protein family that 
regulates nascent folding as well as modulates the fate of 
unstructured or pathologically misfolded proteins, termed 
clients [1]. Misfolded or intrinsically unfolded clients of   
the chaperone network expose hydrophobic signatures   
that Hsps recognize and bind. Hsps attach to clients in these 
hydrophobic regions and, via  a well-coordinated system   
of co-chaperone interactions, are routed for renaturation   
(if suitable) or degradation.  
  Neurodegenerative disorders such as tauopathies are 
characterized by the pathological aggregation of misfolded 
proteins. Thus, Hsps have become a promising system that 
may serve as a platform to modulate disease processes where 
protein misfolding is a common feature. Insofar, there have 
been several promising attempts to manipulate Hsps by 
pharmacological interventions [2, 3] and gene-delivery ap-
proaches [4-10]. 
  The aim of this review is to chronicle strides in the inves-
tigation of Hsps from the perspective of Alzheimer’s disease 
(AD), the most common tauopathy, where intracellular tan-
gles and extracellular amyloid plaques are pathological hall-
marks. In particular, this review will focus on pharmacolo- 
gical therapeutics and genetic interventions to modulate 
Hsp70 and Hsp90. Finally, the current findings on research 
involving both Hsp27 in AD will be presented.  
ALZHEIMER’S DISEASE 
  Alzheimer’s disease is a chronic neurodegenerative   
disorder characterized by progressive memory loss. Currently, 
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5.3 million people in the U.S. have AD. There are an esti-
mated 4% of AD cases in persons younger than 65. Fifty 
percent of the U.S. population older than 85 has AD. Alz-
heimer’s is the most common form of dementia and, with 
diabetes, it is the 7
th leading cause of death in the U.S. Be-
tween 2000 and 2006, deaths because of AD increased by 
over 46%. It is projected that by midcentury, the number of 
AD patients will rise to 11-16 million [11].  
  Pathologically, AD hallmarks consist of aggregates of 
two abnormally folded proteins [12, 13]: beta-amyloid (A) 
[14] and tau [15-17]. Recent data have suggested that large 
aggregates of these two proteins do not induce neurotoxicity, 
but rather small protofibrils of each may be responsible for 
disease pathogenesis [18-20]. In the case of amyloid, (A, 
mostly its 42-amino acid version) accumulation occurs in the 
extracellular space into senile plaques. It is thought that in-
ternalization of A oligomers by the neuron may be respon-
sible for the cascade of detrimental events to the cell includ-
ing tau tangle formation [21, 22].  
CHAPERONE-BASED THERAPIES FOR ALZHEIMER’S 
DISEASE AND OTHER TAUOPATHIES 
  Chaperones are important in tau processing and likely 
participate in abnormal tau accumulation [23-31]. A major 
component of the chaperone network is the Hsp70 family of 
proteins (Hsp70) that folds and degrades nascent and mis-
folded polypeptides [32, 33]. These can operate alone or in 
concert with another major chaperone protein, Hsp90. Hsp70 
functions as a monomer with a single ATP-binding pocket 
and interacts with DnaJ proteins (Hsp40s). DnaJ proteins 
alter the rate of ATP consumption and play an important role 
in client delivery to Hsp70. Conversely, Hsp90 functions as a 
homo-dimer with four ATP-binding pockets and does not 
interact with DnaJ proteins. The higher consumption of ATP 
by Hsp90 has enabled more robust screening efforts that 
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Hsp90 have been implemented in the clinic and are the first-
in-class for chaperone-based therapeutics [34]. Modulators 
of Hsp70 have been difficult to identify because of its low 
intrinsic consumption of ATP. Recent work has consistently 
demonstrated that genetic manipulation of Hsp70, rather than 
Hsp90, has a considerably greater impact on the stability of 
proteins associated with neurodegenerative disease, includ-
ing tau [26, 28, 35-38]. With this in mind, we recently 
worked to identify the impact of chemical modulators of 
Hsp70 ATPase function on tau stability [39].  
THE PARADOX OF CHAPERONE-BASED THERAPIES 
  We recently identified several compounds that either 
stimulate or inhibit the ATPase function of Hsp70 without 
inducing its expression [39-42]. These compounds generi-
cally bind to all Hsp70 family members and allosterically 
affect their rate of ATP consumption, which is tied to open-
ing and closing of the protein lid over the substrate-binding 
domain [40]. Normally, chaperones primarily assist in pro-
tein folding and stabilization [43, 44]. But in neurodegenera-
tive disease, where abnormal proteins accumulate, the role of 
chaperones may be much more diverse. Chaperones may 
preserve abnormal proteins rather than get rid of them, in an 
attempt to restore their function. Chaperones may also facili-
tate the degradation of misfolded disease-associated proteins 
they cannot repair. More recently it has been suggested that 
chaperones actually facilitate aggregation of disease-related 
proteins to prevent toxic aggregates from forming [2, 10, 45-
47]. Based on these findings, much of the effort in chaperone 
research has focused on altering the expression levels of 
these heat shock proteins by activating the heat shock tran-
scription factor (HSF1), and lead compounds have been 
identified that can cause this global response [48, 49]. In-
creasing heat shock protein levels might be expected to allow 
more abnormal protein clients to be bounded by the heat 
shock network and triaged for degradation; however, by 
overexpressing Hsps in several mammalian cell models of 
tauopathy, we have found that such increases may not be 
sufficient to facilitate client degradation [2]. In fact, increas-
ing the levels of some heat shock proteins may actually pre-
serve clients. This phenomenon suggests that there is a de-
gree of antagonism that is built into the chaperone system 
[50]. Instead, inhibiting the ATPase activity of Hsp70 and 
Hsp90 proteins may be a much more effective strategy for 
dictating client fate [2, 39]. Perhaps the most effective strat-
egy to reduce target clients would be to first increase levels 
of heat shock proteins, which would form more Hsp/client 
complexes, and then inhibit the ATPase activity of the chap-
erones to force client degradation, subverting any attempts at 
client repair. 
HSP27 
  Another subset of chaperones that has received limited 
attention from a drug discovery perspective is the small heat 
shock protein (sHsp) family, which consists of Hsps of mo-
lecular weight less than 30 kDa. These sHsps are conserved 
throughout all phyla [1], and despite structural differences, 
their primary role is to bind unfolded proteins and prevent 
them from aggregating, which creates a reservoir of interme-
diates for reactivation [51]. It is thought that these proteins 
can prevent pathological aggregation of tau, and other amy-
loidogenic clients [23, 52, 53]. They are unique molecular 
chaperones in that they function independently of ATPase 
activity [54]; instead, sHsps perform chaperone functions by 
cycling between phosphorylation-dependent oligomers and 
smaller-order states [55]. Among some of their functions, 
sHsps participate in cell survival, cytoskeletal motility, and 
disruption of protein aggregation [56-59]. It is the latter 
function that makes sHsps of great interest as a therapeutic 
intervention for diseases of intracellular protein aggregation 
like tauopathies and other neurodegenerative disorders. 
  Due to its particular function as a disrupter of protein 
aggregation [60], the Hsp of 27 kDa, Hsp27, is a recent tar-
get of interest to the field of tauopathy research. However, 
unlike more classical chaperones like Hsp70 and Hsp90, the 
current knowledge of Hsp27 function is scarce. This may be 
due in part to the unique nature of Hsp27 as an ATPase-
independent chaperone [54], which inherently makes it diffi-
cult to establish functional assays. Furthermore, Hsp27’s 
function is determined by a dramatic, phosphorylation-
dependent change in quaternary structure; this dynamism 
makes the elucidation of structure-function relationships 
very challenging. During quiescent conditions, Hsp27 mostly 
exists as a large oligomeric conformer of 200kDa-800kDa 
[61, 62]. Upon a stress response, it becomes phosphorylated 
at three serine sites (S15, S78, and S82). As a result, phos-
phorylated Hsp27 breaks apart into a smaller conformation 
of monomers, dimers, and tetramers that allow scavenging of 
misfolded polypeptides favorable. It is presumed that clients 
interact with the smaller assemblies of Hsp27 [51, 60, 63, 
64]. Next, the client-bound Hsp27 resurges into a large oli-
gomeric complex while still bound to client, as suggested by 
studies in other sHsps [60, 65, 66]. Experimental evidence 
using Hsp27 mutants retained in either pseudo-phosphory-
lated or perpetually dephosphorylated conformations sug-
gests that it is the latter assembly that results in chaperone 
function. Albeit these results, recent evidence from our labo-
ratory suggest that the processes are more complex in that 
the dynamic cycling from small to large structures is neces-
sary for proper Hsp27 chaperone function in the dissolution 
of toxic protein aggregates [10]. 
  Hsp27 is the human heat shock protein of 27 kilodaltons, 
which is encoded by a single intronless gene termed HSPB1. 
The mouse homolog is Hsp25. The gene resides on chromo-
some 7q11.23, and mutations in it have been associated with 
Charcot-Marie Tooth syndrome, a distal motor and sensory 
neuropathy that is caused by mis-aggregation of the Hsp27 
protein itself [67]. Both the amino- and carboxy-termini of 
Hsp27 allow it to interact with other proteins [62]. The car-
boxy-terminus of all sHsps, including Hsp27, is character-
ized by having a conserved region that is related to the verte-
brate lens protein -crystallin [68, 69]. Hsp27’s -crystallin 
domain is located between residues 87 and 167 [68]. In 
1982, Ingolia and Craig hypothesized that since -crystallins 
in the lens form soluble multimers then this shared domain 
would also facilitate Hsp27 oligomerization Ingolia and 
Craig 1982 PNAS). Indeed, experimental evidence using 
site-directed spin labeling indicated that the -crystallin  
domain of Hsp27 is critical for the formation of discreet   
oligomeric structures with symmetrical orientation [70].   
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domain. It is characterized by a conserved tryptophan-
aspartate-proline-phenylalanine sequence, and it lies at the 
N-terminus. Unlike the -crystallin domain, the WDPF   
domain is sensitive to phosphorylation, and this process is 
critically linked to the multimerization of Hsp27 [62].  
  Functional modulation of human Hsp27 is triggered by 
phosphorylation at three key sites (S15, S78, and S82) by the 
p38 mitogen-activated protein kinase mitogen-activated pro-
tein kinase (MAPK)-activated protein kinase 2 and Akt 
pathway (for a thorough review see [71]). Phosphorylation of 
Hsp27 is reversible and dephosphorylation is mainly attrib-
uted to protein phosphatase 2A [72]. The result of cycling 
between phosphorylated and dephosphorylated states causes 
Hsp27 to rearrange from smaller assemblies to large self-
aggregated rearrangements. This dynamic process results in 
a dual and independent function of Hsp27, both as a regula-
tor of actin microfilament dynamics and as a molecular 
chaperone that prevents unfolded protein aggregation [62] 
Fig. (1).  
  Before its identification, Hsp27 had been functionally 
defined as an inhibitor of actin polymerization in smooth 
muscle of turkey gizzards [73, 74]. It was later found that 
stress-induced actin depolymerization was partially blocked 
in CHO cells over-expressing Hsp27 [75]. This relationship 
was further evaluated using CHO cells over-expressing ei-
ther wild-type Hsp27 or an Hsp27 mutant that is phosphory-
lation incompetent: only wild-type Hsp27 could stabilize 
actin filaments under stress [76], Thus it can be suggested 
that Hsp27 phosphorylation is a critical process for Hsp27 
function. This finding was also corroborated by a time-
course study in thrombin-activated platelets showing that 
unbound, cytoplasmic Hsp27 must be phosphorylated before 
it can attach to actin [77]. Phosphorylation kinetics are not 
responsible for Hsp27 cellular localization, but they are re-
quired for regulating microfilament formation [78, 79]. It 
was determined that only unphosphorylated, monomeric 
Hsp27 is able to block actin polymerization [80], and there-
fore manipulation of Hsp27 phosphorylation state enables 
genetic regulation of pinocytosis [76], cell migration [81-83], 
and muscle contraction [73, 74], among many others.  
  The other major role of Hsp27 is that of a molecular 
chaperone; however, the mechanism contributing to this ac-
tivity is less clear. To date, it is thought that only large mul-
timeric Hsp27 complexes are capable of chaperone activity 
[55]. This is largely based on evidence that substrates/clients 
have previously been detected attached to Hsp27 oligomers 
[51, 60, 63, 64]. The ultimate fate of the bound client is 
likely driven by interactions with specific co-chaperones and 
the extent of damage to the misfolded client. Data from in 
vivo and in vitro experiments show that Hsp27 can prevent 
self-association of aggregation prone polypeptides like the 
insulin B chain upon disulphide reduction, malate dehydro-
genase, and citrate synthase, among others [51, 63, 84]. In 
addition, Hsp27 can also hold misfolded or intrinsically dis-
ordered clients such as tau in a conformation that is stable for 
subsequent transfer to Hsp70, culminating in client refolding 
at the expense of ATP [51]. Hsp27 can also deliver clients 
for ubiquitin-independent clearance via the proteasome in a 
mechanism that is not well characterized [23], but it likely 
involves other chaperones such as Hsp90 and the ubiquitin 
ligase CHIP [24] Fig. (2). It is this capacity of Hsp27 to hold 
and prevent aggregation of unfolded clients that is interesting 
for neurodegenerative disorders like tauopathies, synuclei-
nopathies, and poly-glutamine diseases, where aggregation 
of misfolded proteins is the confounding pathogenic hall-
mark. Thus, enhancing Hsp27 levels or function to prevent 
aggregation of these toxic elements, may serve as a potential 
therapeutic strategy in neurodegenerative diseases. 
HSP27 EXPRESSION AND LOCALIZATION IN THE 
CNS IS SITE- AND CELL-SPECIFIC 
  Hsp27 is detectable under basal conditions in both a site 
and cell-specific manner in the central nervous system 









Fig. (1). The necessity of phosphorylation-dependent Hsp27 function for preventing protein aggregation of unfolded intermediates. Large 
molecular weight Hsp27 multimers are constitutively present in the cell under basal conditions. Upon extracellular stress, the p38 MAP 
kinase pathway is activated, phosphorylating Hsp27 (red circles). Consequently, the Hsp27 multimeric complex disassembles into smaller 
complexes that can bind the denatured client and prevent its subsequent aggregation. The client can then be targeted for degradation in a 
mechanism that is independent of ubiquitin. Without Hsp27, folding intermediates of the client would be prone to aggregate. 626    Current Neuropharmacology, 2011, Vol. 9, No. 4  Abisambra et al. 
and during development also adhere to specific anatomical 
patterns. Moreover, differentiating cells are Hsp27 immuno-
reactive, while apoptotic cells lack Hsp27 expression [85]. 
This suggests that Hsp27 participates in cell survival during 
development and into adulthood [4, 6, 86, 87].  
  Under basal conditions, Hsp27 immuno-reactivity is 
scarce but detectable in motor and sensory neurons of the 
spinal cord and brain stem [88], most ocular neural structures 
[89], and a small set of Purkinje cells in mouse cerebellum 
[90-92]. Levels of constitutive Hsp27 are highest in astro-
cytes surrounding leptomeningeal and parenchymal blood 
vessels [93]. Meanwhile, other brain regions are virtually 
devoid of constitutive Hsp27 immuno-reactivity, and if 
found, it’s mostly in glial populations [93-99].  
  Site-specific up-regulation of Hsp27 is detected upon 
stimulation by various stress triggers. For instance, while 
Hsp27 is barely detectable in the cortex and hippocampus of 
un-injured rats [88, 98], it is induced in these regions upon 
stressors like hyperthermia and ischemia [96-98]. Hyper-
thermia also stimulates Hsp27 expression in large glial popu-
lations and some neurons of forebrain, brain stem, hypo-
thalamus, and cerebellum [100-102]. Other examples of 
stress-related Hsp27 inducers include; middle cerebral artery 
occlusion [97, 100, 101], traumatic nerve injury [103-106], 
and kainic acid-induced epilepsy [95, 99, 100, 102].  
HSP27 AND AD 
  In addition to the stressors described above, Hsp27 is 
also increased in the brains of AD patients [107-109]. This 
phenomenon could be explained by the convergence of a 
variety of stress insults that occur in the AD brain, including 
oxidation, inflammation, or aberrant calcium influx [110, 
111]. This up-regulation of Hsp27 appears to be site and cell-
specific. For instance, using immuno-histochemical, sand-
wich ELISA, and dot blot analyses, several groups deter-
mined that AD brains express significantly increased levels 
of Hsp27 in the frontal, parietal, and temporal cortices, but 
not in occipital cortex when compared to age-matched non-
demented controls; specifically, Hsp27 co-localized with 
areas affected by senile plaques and cerebral amyloid an-
giopathy [53, 93, 107, 109]. Constitutive Hsp27 expression 
in control brains was mostly found in glia surrounding lep-
tomeningeal and parenchymal blood vessels and occasion-
ally in a scarce number of astrocytes throughout the cortex of 
control brains, as described above [107].  
  This distribution suggests that efforts to increase the lev-
els of Hsp27 in neurons may be a neuro-protective strategy 
in AD [95-99]. For example, one family of compounds that 
specifically upregulates Hsp27 expression without affecting 
the expression of other Hsps is the statins [112-118]. Indeed 
statins are proposed to have therapeutic efficacy for AD 
[119-123] and increasing Hsp27 levels may be one of several 
mechanisms that are beneficial for tau-bearing neurons. Thus 
identifying therapeutics that specifically upregulate Hsp27 in 
neurons may reduce the extent of neuronal damage, prevent 
neuronal death, and increase neuronal function despite neu-
rotoxic stressors. As a counterpoint to this approach, it is 
important to consider the possible negative consequences to 
the neuron that result from sustained up-regulation of Hsp27 
protein levels. Perpetual induction of Hsp27 may ultimately 
be detrimental over time. Perhaps intermittent delivery 
strategies that temporally upregulate Hsps like Hsp27 may 
be the most sustainable and effective way to target these pro-
teins therapeutically.  
HSP27 AND A 
  The capacity of Hsp27 to ameliorate amyloid  (A)-























Fig. (2). Coordination of substrate transport through the chaperone 
network. Upon stress induced microtubule disassembly, Hsp27 and 
perhaps other small Hsps, bind tau to prevent its toxic aggregation. 
The Hsp27/tau complex is stable, and tau can then be transferred to 
the Hsp70/DnaJ chaperone complex. If refolding is not possible, the 
tau-bound Hsp70 complex will associate with the Hsp90 complex 
for further attempts at refolding. Alternatively, the client is proc-
essed for degradation. The decisions are made based on coordinate 
regulation by the chaperones and cochaperones associating with the 
complex, such as Hsp90, CHIP and Hop. Exploiting the Diversity of the Heat-Shock Protein  Current Neuropharmacology, 2011, Vol. 9, No. 4    627 
vitro experiments [94]. Primary cortical neurons of P1 rats 
over-expressing Hsp27 showed reduction in Aß-mediated 
cell death, increased neurite outgrowth, and mitochondrial 
protection from Aß-induced damage [94]. Importantly, only 
neuronal Hsp27 conferred survival; changes to glial or endo-
thelial Hsp27 levels were not protective. These results cor-
roborate previous work showing that Hsp27 could abrogate 
A aggregation and toxicity [124-126]. Three independent 
studies show that Hsp27 binds A, whether it be in the form 
of A40 [126], A42 [94], or a particular variant of Aß40  
that carries the Dutch mutation (D-A40) [124]. Aggregation 
of the different Aß subtypes was also decreased upon   
incubation with Hsp27, except when Aß42 fibrils formed 
[125]. Together, these results suggest that Hsp27 binds   
aggregation-prone A, reduces its ability to assemble into 
fibrils, and consequently confers protection from cell death. 
HSP27 AND TAU 
  In addition to Aß, Hsp27 also associates with tau tangles 
in AD, as well as other tauopathies including progressive 
supranuclear palsy, corticobasal degeneration and fronto-
temporal dementia [53, 127, 128]. Interestingly, while bio-
chemical assays show increased total levels of Hsp27 in AD, 
immuno-staining assays reveal that the bulk of Hsp27 (apart 
from that found in tangles) is found in glia, particularly as-
trocytes.  
  In 2004, Shimura et al. more thoroughly evaluated the 
interaction of Hsp27 with tau [23]. Using human brain 
lysates from both AD and age-matched control individuals, 
they identified Hsp27 as a direct binding partner of phos-
phorylated tau. These results were later corroborated in 
larger studies of AD brains, where Hsp27 levels were shown 
to correlate with neurofibrillary tangle pathology progression 
[53, 127, 128]. The interaction between Hsp27 and tau was 
enhanced by phosphorylation of either protein [23]. While 
these findings suggest that Hsp27 preferentially interacts 
with aberrant tau, the persistence of tangles in the brain of 
AD patients despite this interaction suggests that Hsp27 
alone is not sufficient to prevent tau pathogenesis. 
  Subsequent experiments in human neuronal-like cells 
revealed that both Hsp27 and its phosphorylated form, 
pHsp27, participated in the dephosphorylation of tau and 
perhaps facilitated tau degradation [23]. Cell culture studies 
showed that both wildtype and phosphorylated Hsp27 were 
able to prevent tau aggregation and prevent apoptosis [23]. 
These results further suggest that Hsp27 is capable of suc-
cessfully preventing pathogenic protein aggregation and at-
tenuating toxicity. But this protection is only imparted dur-
ing stress. Therefore, chemical or genetic induction of neu-
ronal Hsp27 could be exploited to protect neurons from the 
adverse consequences of intra-neuronal tangle accumulation.  
CONCLUDING REMARKS 
 Although  in vitro and in vivo experimental efforts have 
yielded successful abrogation of AD pathology by inhibiting 
Hsp70 and Hsp90, the translation of these approaches to hu-
man therapeutics may lead to complications in many other 
biological processes linked to the normal functioning of 
these proteins, and therefore lead to undesirable outcomes. 
As such, Hsp70 and Hsp90 inhibition become unattractive 
therapeutic targets. However, such experimental success 
paves the road to focus on Hsps as powerful tools to combat 
diseases rooted in the abnormal aggregation of proteins in 
cells. A shift of attention to explore the family of sHsps has 
procured data highlighting the impact of Hsp27 on prevent-
ing disease progression [10].  
  Any therapeutic strategy aimed at up-regulating Hsp27 
levels must override the cell’s natural tendency to express 
low levels of endogenous Hsp27. For instance, the murine 
leukemic cell line P388 is incapable of expressing endoge-
nous Hsp25 despite heat shock stimulation [129]. It is possi-
ble that P388 cells have an Hsp25 gene silencing mechanism 
since HeLa cells transfected with the P388 Hsp25 promoter 
were capable of inducing expression. Whether neurons are 
under similar regulatory constraints that subdue Hsp27 ex-
pression remains to be determined. However, this regulation 
of Hsp27 is not confined to all neurons. In fact, Hsp27 in-
duction is observed after ischemic stress in rat neurons of the 
fourth and fifth cortical layers and pyramidal neurons in the 
hippocampus [97]. Besides endogenous production as a pri-

















Fig. (3). The variable affinity of phylogenetically diverse sHsps for 
tau may be therapeutically relevant. Client specificity of sHsps is not 
well characterized. Small Hsp-mediated prevention of toxic tangle 
formation can be further enhanced by selecting sHsps, perhaps even 
from other species, with higher affinity for tau and driving their ex-
pression. Therefore certain sHsps will likely bind tau quicker and 
more stably, intervening before tau can begin to aggregate. 628    Current Neuropharmacology, 2011, Vol. 9, No. 4  Abisambra et al. 
to determine if these neurons are capable of internalizing 
glial-Hsp27 therefore exploring a secondary mechanism for 
increased neuronal Hsp27. Other possible means to enhance 
Hsp27 levels could include slowing neuronal Hsp27 turnover 
or even extrinsically delivering recombinant sHsps derived 
from other organisms. It is possible that these homologous 
versions of Hsp27 may have even more potent activity for 
reducing aggregation than human Hsp27 itself Fig. (3).  
  Further understanding of the mechanisms regulating neu-
ronal Hsp27 expression will provide insight for the devel-
opment of new therapies. A neuron-specific strategy may be 
the most effective for treating neurodegenerative tauopathies, 
the most common of which is AD. Furthermore, this review 
has focused on only one of the many members of the large 
and conserved family of sHsps. The complex regulation of 
this phylogenetically conserved group of proteins may coor-
dinate their activities to clear the pathological inclusions 
associated with AD. Defining these mechanisms will likely 
lead to improved rational drug design for targeting pro-
teotoxic diseases. 
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